This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nikonenko, B. V. Articles by Nacy, C. A. Search for Related Content PubMed PubMed Citation Articles by Nikonenko, B. V. Articles by Nacy, C. A.

Rapid, Simple In Vivo Screen for New Drugs Active against Mycobacterium tuberculosis

Sequella, Inc., Rockville, Maryland,¹ Central Research Institute for Tuberculosis, Moscow, Russia²

Received 22 March 2004/ Returned for modification 21 May 2004/ Accepted 18 June 2004

We evaluated the use of a simple and easy-to-obtain potential marker of tuberculosis (TB) drug efficacy, body weight, and correlated weight loss or gain with the number of CFU of Mycobacterium tuberculosis in lungs and spleens of infected mice. C3H mice were infected intravenously with 10⁶ CFU of virulent M. tuberculosis H37Rv, and body weight was evaluated for several weeks after infection. At day 20, infected untreated mice consistently lost more than 25% of their body weight. Chemotherapy with selected orally active anti-TB drugs was initiated 7 days following infection and continued for 13 days. Drugs that were administered daily by gavage included isoniazid (INH), ethambutol (EMB), rifampin (RIF), and moxifloxacin (MXF). At the most effective doses, each of these drugs inhibited bacterial growth and abolished infection-induced body weight loss. Chemotherapy with 1/10 the standard dose of INH determined in accepted long-term murine models of TB also prevented body weight loss, while chemotherapy with 1/10 the standard dose of RIF did not. With only 2 weeks of chemotherapy, we observed a good reverse correlation between CFU in lung or spleen and body weight of mice. The simple measurement of weight in TB-infected drug-treated mice required only a weight balance, and go/no-go drug efficacy data was available on day 20 without the necessity of prolonged drug treatment and long (3 weeks or more) in vitro culture times to obtain organ CFU values.

This article has been cited by other articles:

• Sosunov, V., Mischenko, V., Eruslanov, B., Svetoch, E., Shakina, Y., Stern, N., Majorov, K., Sorokoumova, G., Selishcheva, A., Apt, A. (2007). Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother 59: 919-925 [Abstract] [Full Text]  
• Nikonenko, B. V., Protopopova, M., Samala, R., Einck, L., Nacy, C. A. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrob. Agents Chemother. 51: 1563-1565 [Abstract] [Full Text]  
• Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L., Nacy, C. A. (2005). Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968-974 [Abstract] [Full Text]